FDA notification lets Anavex proceed with its planned blarcamesine study for Fragile X syndrome, a positive step for its drug program. No study results or treatment approval were reported, so benefits remain unproven.
This lets Anavex test blarcamesine in a planned study for Fragile X syndrome. The notice reports no study results or treatment approval, so it marks progress, not proof the drug works.
Follow Anavex Life Sciences Corp. (AVXL) free. When we publish a story about it, you get the plain-English explanation as an alert.
Get alerts for AVXL